Brief: China Medical System Holdings - Via Unit Entered License, Collaboration And Supply Agreement With Hefei Tianmai Biotechnology Development
15/08/2022 15:04
China Medical System Holdings Ltd 0867.HK :
* CHINA MEDICAL SYSTEM HOLDINGS - VIA UNIT ENTERED LICENSE,
COLLABORATION AND SUPPLY AGREEMENT WITH HEFEI TIANMAI
BIOTECHNOLOGY DEVELOPMENT
* CHINA MEDICAL SYSTEM - DEAL FOR SECOND-GENERATION INSULIN
SERIES PRODUCTS AND THIRD-GENERATION INSULIN ANALOGUE GLARGINE
INSULIN INJECTION
Source text for Eikon: ID:
Further company coverage: 0867.HK
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says